These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 24975702

  • 1. New predictive approaches for ITI treatment.
    Minno GD, Santagostino E, Pratt K, Königs C.
    Haemophilia; 2014 Sep; 20 Suppl 6():27-43. PubMed ID: 24975702
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.
    Oldenburg J, Austin SK, Kessler CM.
    Haemophilia; 2014 Sep; 20 Suppl 6():17-26. PubMed ID: 24975701
    [Abstract] [Full Text] [Related]

  • 4. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
    Santagostino E.
    Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
    [Abstract] [Full Text] [Related]

  • 5. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM.
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [Abstract] [Full Text] [Related]

  • 6. Immune tolerance induction in patients with hemophilia A.
    Astermark J.
    Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T, GTH PUP Study Group.
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [Abstract] [Full Text] [Related]

  • 10. Immune tolerance: critical issues of factor dose, purity and treatment complications.
    DiMichele DM.
    Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The role of VWF for the success of immune tolerance induction.
    Kreuz W.
    Thromb Res; 2008 Dec; 122 Suppl 2():S7-S12. PubMed ID: 18549910
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G, Spranger T, Brackmann HH.
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.